Skip to Main Content

Author Details

Robert A Davey
Boston University
1991
111
34
Nevan J Krogan (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
36117402Anti-SARS-CoV-2 activity of targeted kinase inhibitors: Repurposing clinically available drugs for COVID-19 therapy.J Med Virol2023
37598728Disruption of Ebola NP<sup>0</sup>VP35 Inclusion Body-like Structures reduce Viral Infection.J Mol Biol2023
37095859The human E3 ligase RNF185 is a regulator of the SARS-CoV-2 envelope protein.iScience2023
36708708Structure of the Inmazeb cocktail and resistance to Ebola virus escape.Cell Host Microbe2023
33907750Identification of druggable host targets needed for SARS-CoV-2 infection by combined pharmacological evaluation and cellular network directed prioritization both in vitro and in vivo.bioRxiv2022
35405107Development of Monoclonal Antibodies to Detect for SARS-CoV-2 Proteins.J Mol Biol2022
35789908Monoclonal antibodies binding data for SARS-CoV-2 proteins.Data Brief2022
35690007Adipocytes are susceptible to Ebola Virus infection.Virology2022
35357134Evaluation of Phenol-Substituted Diphyllin Derivatives as Selective Antagonists for Ebola Virus Entry.ACS Infect Dis2022
36680083Inactivation of Ebola Virus and SARS-CoV-2 in Cell Culture Supernatants and Cell Pellets by Gamma Irradiation.Viruses2022
36146710CAPG Is Required for Ebola Virus Infection by Controlling Virus Egress from Infected Cells.Viruses2022
35997284Marburg Virus VP30 Is Required for Transcription Initiation at the Glycoprotein Gene.mBio2022
35992305Identification of potent inhibitors of SARS-CoV-2 infection by combined pharmacological evaluation and cellular network prioritization.iScience2022
36007601Ligand-based design of peptide entry inhibitors targeting the endosomal receptor binding site of filoviruses.Antiviral Res2022
33417854Actionable Cytopathogenic Host Responses of Human Alveolar Type 2 Cells to SARS-CoV-2.Mol Cell2021
33827988ORF10-Cullin-2-ZYG11B complex is not required for SARS-CoV-2 infection.Proc Natl Acad Sci U S A2021
33762578Inhibition of HECT E3 ligases as potential therapy for COVID-19.Cell Death Dis2021
33705865Identification of filovirus entry inhibitors targeting the endosomal receptor NPC1 binding site.Antiviral Res2021
34583312Synthesis and antiviral activity of fatty acyl conjugates of remdesivir against severe acute respiratory syndrome coronavirus 2 and Ebola virus.Eur J Med Chem2021
34260076Non-canonical proline-tyrosine interactions with multiple host proteins regulate Ebola virus infection.EMBO J2021
34232742A Naturally Occurring Polymorphism in the Base of Sudan Virus Glycoprotein Decreases Glycoprotein Stability in a Species-Dependent Manner.J Virol2021
33426509A multi-pronged approach targeting SARS-CoV-2 proteins using ultra-large virtual screening.iScience2021
33445537Automation of Infectious Focus Assay for Determination of Filovirus Titers and Direct Comparison to Plaque and TCID<sub>50</sub> Assays.Microorganisms2021
32231668Egyptian Rousette IFN-Ï¿ Subtypes Elicit Distinct Antiviral Effects and Transcriptional Responses in Conspecific Cells.Front Immunol2020
33200116A Multi-Pronged Approach Targeting SARS-CoV-2 Proteins Using Ultra-Large Virtual Screening.ChemRxiv2020
32886512Screening and Reverse-Engineering of Estrogen Receptor Ligands as Potent Pan-Filovirus Inhibitors.J Med Chem2020
32682926Pyronaridine tetraphosphate efficacy against Ebola virus infection in guinea pig.Antiviral Res2020
32870648High-Throughput Screening Assay to Identify Small Molecule Inhibitors of Marburg Virus VP40 Protein.ACS Infect Dis2020
32869031Elucidation of remdesivir cytotoxicity pathways through genome-wide CRISPR-Cas9 screening and transcriptomics.bioRxiv2020
32490678Discovery and Structural Optimization of 4-(Aminomethyl)benzamides as Potent Entry Inhibitors of Ebola and Marburg Virus Infections.J Med Chem2020
30729228Ebola Virus Bayesian Machine Learning Models Enable New in Vitro Leads.ACS Omega2019
31751347Repurposing the antimalarial pyronaridine tetraphosphate to protect against Ebola virus infection.PLoS Negl Trop Dis2019
31413797DABMA: A Derivative of ABMA with Improved Broad-Spectrum Inhibitory Activity of Toxins and Viruses.ACS Med Chem Lett2019
31101988The Natural Product Eugenol Is an Inhibitor of the Ebola Virus In Vitro.Pharm Res2019
29175127Retro-2 and its dihydroquinazolinone derivatives inhibit filovirus infection.Antiviral Res2018
29860496Development of Clinical-Stage Human Monoclonal Antibodies That Treat Advanced Ebola Virus Disease in Nonhuman Primates.J Infect Dis2018
30144461Inhibiting pyrimidine biosynthesis impairs Ebola virus replication through depletion of nucleoside pools and activation of innate immune responses.Antiviral Res2018
29947774Autophagy-Associated Proteins Control Ebola Virus Internalization Into Host Cells.J Infect Dis2018
30550789Protein Interaction Mapping Identifies RBBP6 as a Negative Regulator of Ebola Virus Replication.Cell2018
30395872Novel amodiaquine derivatives potently inhibit Ebola virus infection.Antiviral Res2018
30513600Identification of Diaryl-Quinoline Compounds as Entry Inhibitors of Ebola Virus.Viruses2018
30335906Phenotypic Prioritization of Diphyllin Derivatives That Block Filoviral Cell Entry by Vacuolar (H<sup>+</sup> )-ATPase Inhibition.ChemMedChem2018
29584652Identification of Ellagic Acid from Plant Rhodiola rosea L. as an Anti-Ebola Virus Entry Inhibitor.Viruses2018
27712998Inhibitors of retrograde trafficking active against ricin and Shiga toxins also protect cells from several viruses, Leishmania and Chlamydiales.Chem Biol Interact2017
29138439ABMA, a small molecule that inhibits intracellular toxins and pathogens by interfering with late endosomal compartments.Sci Rep2017
28601947Mechanisms of Filovirus Entry.Curr Top Microbiol Immunol2017
27001363Treatment of blood with a pathogen reduction technology using ultraviolet light and riboflavin inactivates Ebola virus in vitro.Transfusion2016
27161622Large-Scale Screening and Identification of Novel Ebola Virus and Marburg Virus Entry Inhibitors.Antimicrob Agents Chemother2016
27185801Discovery of a Broad-Spectrum Antiviral Compound That Inhibits Pyrimidine Biosynthesis and Establishes a Type 1 Interferon-Independent Antiviral State.Antimicrob Agents Chemother2016
27282782Corrigendum: Facile Discovery of a Diverse Panel of Anti-Ebola Virus Antibodies by Immune Repertoire Mining.Sci Rep2016
  • 1 - 50 of 111

Recommended Authors

Hannah S Sperber
Institute for Translational HIV Research, University Hospital Essen
Career Start Year 2017
Number of shared co-authors 1
Stuart Weston
University of Maryland School of Medicine
Career Start Year 2014
Number of shared co-authors 9
Jesus A Silvas
Texas Biomedical Research Institutegrid.250889.e
Career Start Year 2014
Number of shared co-authors 7
Elizabeth A Nelson
Cardiovascular Research Center, University of Virginia School of Medicine
Career Start Year 2014
Number of shared co-authors 2
Andreas S Puschnik
Stanford University School of Medicine
Career Start Year 2013
Number of shared co-authors 1
Maxime Chazal
CNRS UMR9, Institut Pasteur, Universite de Paris Cite
Career Start Year 2012
Number of shared co-authors 6
Roland Schwarzer
University Hospital Essen, Institute for Translational HIV Research
Career Start Year 2012
Number of shared co-authors 2
Craig B Wilen
Yale School of Medicine
Career Start Year 2010
Number of shared co-authors 2
Carles Mart??nez-Romero
Icahn School of Medicine at Mount Sinai
Career Start Year 2009
Number of shared co-authors 3
Blandine Monel
Institut Pasteur, CNRS UMR 3569
Career Start Year 2009
Number of shared co-authors 2
Hans-Heinrich Hoffmann
The Rockefeller University
Career Start Year 2008
Number of shared co-authors 1
Lisa Miorin
Icahn School of Medicine at Mount Sinai
Career Start Year 2008
Number of shared co-authors 10
Colm Atkins
Rutgers University
Career Start Year 2007
Number of shared co-authors 4
Charlotte A Stoneham
University of California
Career Start Year 2006
Number of shared co-authors 3
Jessica L Smith
Vaccine and Gene Therapy Institute, Oregon Health and Science University
Career Start Year 2005
Number of shared co-authors 0
Yaw Shin Ooi
Duke-NUS Medical School
Career Start Year 2003
Number of shared co-authors 2
Nolwenn Jouvenet
CNRS UMR9, Institut Pasteur, Universite de Paris Cite
Career Start Year 2003
Number of shared co-authors 6
Shirit Einav
Stanford University School of Medicine
Career Start Year 2002
Number of shared co-authors 1
Balaji Manicassamy
University of Iowa
Career Start Year 2002
Number of shared co-authors 4
Luis Martinez-Sobrido
Texas Biomedical Research Institute
Career Start Year 2001
Number of shared co-authors 12
Sonja M Best
National Institute of Allergy and Infectious Diseases, National Institutes of Health
Career Start Year 1998
Number of shared co-authors 5
J??rgen Haas
University of Edinburgh
Career Start Year 1996
Number of shared co-authors 0
Jan E Carette
Stanford University School of Medicine
Career Start Year 1996
Number of shared co-authors 2
Abraham L Brass
University of Massachusetts Medical School
Career Start Year 1995
Number of shared co-authors 4
Benhur Lee
Icahn School of Medicine at Mount Sinai
Career Start Year 1995
Number of shared co-authors 8
Paul D Bieniasz
The Rockefeller University
Career Start Year 1993
Number of shared co-authors 0
Matthew B Frieman
Center for Pathogen Research, University of Maryland School of Medicine
Career Start Year 1993
Number of shared co-authors 12
Alec J Hirsch
Vaccine & Gene Therapy Institute, Oregon Health & Science University
Career Start Year 1992
Number of shared co-authors 0
Ren Sun
University of California los angeles
Career Start Year 1992
Number of shared co-authors 3
Olivier Schwartz
Institut Pasteur, Universite Paris Cite, CNRS UMR9
Career Start Year 1987
Number of shared co-authors 4

Collaborators

Manu Anantpadma
Boston University
Co-authored papers 27
Olena Shtanko
Texas Biomedical Research Institute
Co-authored papers 9
Wendy Maury
Carver College of Medicine, University of Iowa
Co-authored papers 9
Daisy W Leung
Washington University School of Medicine
Co-authored papers 8
Christopher F Basler
Icahn School of Medicine at Mount Sinai
Co-authored papers 8
Gaya K Amarasinghe
Washington University School of Medicine at St. Louis
Co-authored papers 7
Elke Mühlberger
Co-authored papers 6
Alexander N Freiberg
University of Texas Medical Branch
Co-authored papers 6
Stephan Becker
Institute of Virology, Philipps University Marburg
Co-authored papers 6
Sina Bavari
Co-authored papers 6
Ann N Reyes
Texas Biomedical Research Institute
Co-authored papers 5
Priya Luthra
Trudeau Institute
Co-authored papers 5
Robert Swanepoel
University of Pretoria
Co-authored papers 4
Jens H Kuhn
National Institute of Allergy and Infectious Diseases, National Institutes of Health
Co-authored papers 4
Steven B Bradfute
Co-authored papers 4
Janusz T Paweska
University of Pretoria
Co-authored papers 4
Mark Namchuk
Blavatnik Institute, Harvard Medical School
Co-authored papers 4
Gary P Kobinger
University of Texas Medical Branch
Co-authored papers 4
Sven Enterlein
Co-authored papers 4
Douglas J LaCount
Purdue University
Co-authored papers 3
Nawneet Mishra
Washington University School of Medicine in St. Louis
Co-authored papers 3
Hans-Dieter Klenk
Institute of Virology, Philipps University
Co-authored papers 3
Caroline G Williams
College of Medicine, University of Florida
Co-authored papers 3
Rekha G Panchal
Co-authored papers 3
Stephen J Elledge
Howard Hughes Medical Institute, Brigham and Women's Hospital, Harvard Medical School
Co-authored papers 3
Dandan Liu
College of Veterinary Medicine, Nanjing Agricultural University
Co-authored papers 2
Jyoti Batra
J. David Gladstone Institutes
Co-authored papers 2
Jennifer M Binning
H. Lee Moffitt Cancer Center and Research Institute
Co-authored papers 2
Nevan J Krogan (CM4AI)
University of California San Francisco
Co-authored papers 2
Lisa A Elferink
University of Texas Medical Branch
Co-authored papers 2
Release 1.2